High-throughput affinity chromatography screening: boosting AAV vector recovery from <1% to >70%

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

High-throughput affinity chromatography screening: boosting AAV vector recovery from <1% to >70%

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

High-throughput condition screening using 96-well affinity chromatography plates can increase AAV5 vector recovery from less than 1% to over 70%. This approach also reduces development timelines from approximately eight weeks to two, lowering costs through efficient scale-down strategies.

This session presents data from a plate-based screening workflow evaluating buffer chemistry and pH variables for AAV affinity capture. Using AAV5 as a case study, attendees will see how conditions identified through 96-well plate screening were validated using 1 mL prepacked columns, delivering enhanced vector purity and compatibility with downstream processing. The same approach was then applied to optimize recovery across additional serotypes.

Attend this session to:

Review data demonstrating how 96-well plate-based condition screening increased AAV vector recovery from less than 1% to over 70%, with selected conditions confirmed using 1 mL prepacked columns
Understand how this scale-down screening approach reduces development timelines from approximately eight weeks to two, lowering costs while maintaining confidence in downstream performance
Understand how buffer chemistry and pH influence AAV capture and elution performance and inform condition selection across serotypes
Learn how optimized affinity capture conditions support improved vector purity and downstream process compatibility across multiple AAV serotypes

Alésia Xemaire

Associate Scientist, Process Development and Industrialization Department at SK Pharmteco EU

Alésia Xemaire is an Associate Scientist in process development at SK Pharmteco EU, based in Corbeil-Essonnes, France. She specializes in the development and optimization of upstream and downstream processes of platforms for AAV and lentiviral vector production from laboratory to pilot scale. She holds an engineering degree in biotechnology from École Nationale Supérieure de Technologie des Biomolécules de Bordeaux (ENSTBB), France.

Nicolas Laroudie

Staff Scientist, Field Applications at Thermo Fisher Scientific

Biochemist by education, Nicolas Laroudie used to work for Généthon, France, between 2001 and 2011 as Head of Downstream Development. He was leading a team in charge of developing and scaling-up purification processes for AAV, retroviral and lentiviral vectors used in gene therapy treatments. He then joined Merck Millipore as a BioManufacturing Engineer where he used to technically support European customers for all DSP technologies - from clarification to sterile filtration, including TFF and systems - with a strong focus on chromatography. In particular, he took an active role in the establishment of a fully continuous, large-scale disposable DSP process for the purification of a monoclonal antibody, within the framework of a large multi-company European consortium. He eventually joined Thermo Fisher Scientific in 2019 as Field Application Specialist for purification, technically supporting the implementation of POROS and CaptureSelect chromatography products for south-western European customers.

You have registered for this webinar